Be the first person to write a business review for Pharmasset, Inc.

POZEN, Inc. was founded in 1996 and is headquartered in Chapel Hill, North Carolina. POZEN, Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has development and commercialization alliances with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers.

Protalex, Inc. company was founded in 1999 and is headquartered in New Hope, Pennsylvania. Protalex, Inc., a development stage company, engages in the development of biopharmaceutical drugs for the treatment of autoimmune and inflammatory diseases in the United States. Protalex company targets the autoimmune diseases rheumatoid arthritis and idiopathic thrombocytopenic purpura. Its lead compound, PRTX-100, is a purified form of the Staphylococcal bacterial protein known as Protein A that has the ability to bind to and to down regulate activation of human B-lymphocytes and macrophages, which are key cells mediating inflammation in certain autoimmune diseases.

RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe.

Reliv' International, Inc. was founded in 1984 and is headquartered in Chesterfield, Missouri. Reliv' International, Inc. is a developer, manufacturer and marketer of a line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management and sports nutrition. The Company offers 16 nutritional supplements and a line of seven skin care products. Its core line of nutritional supplements, which represented 64.5% of net sales, during the year ended December 31, 2008, includes four products: Reliv Classic and Reliv NOW, two basic nutritional supplements containing a full and balanced blend of vitamins, minerals, proteins and herbs; Innergize!, an isotonic sports supplement in three flavors, and FibRestore, a high-fiber and antioxidant supplement. The Company’s product line includes nutritional supplements that address basic nutrition, specific wellness needs, weight management and sports nutrition.

Santarus was founded in 1996 and is based in San Diego, California. Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of traveler’s diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.